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A B S T R A C T
Background: Immune reconstitution therapies (IRT) for patients with multiple sclerosis are used for short, in-
termittent treatment periods to induce immune resetting and allow subsequent treatment-free periods.
Cladribine tablets are postulated to be an IRT that causes selective and transient reductions in CD19+ B cells and
T cells, followed by reconstitution of adaptive immune function.
Objective: To characterize long-term lymphocyte count changes in pooled data from the 2-year CLARITY and
subsequent 2-year CLARITY Extension studies, and the PREMIERE registry (Long-term CLARITY cohort).
Methods: Data from patients randomized to placebo (n=435) or cladribine tablets 10mg (MAVENCLAD®; 3.5mg/
kg cumulative dose over 2 years, referred to as cladribine tablets 3.5mg/kg; n=685) in CLARITY or CLARITY
Extension, including time spent in the PREMIERE registry were pooled to provide long-term follow-up data. The
study investigated absolute lymphocyte counts (ALC) up to 312 weeks and B and T cell subsets up to 240 weeks after
the first dose, in patients receiving placebo or cladribine tablets 3.5mg/kg administered as two short (4 or 5 days)
weekly treatments at the start of months 1 and 2 in each treatment year, followed by no further active treatment.
Results: Treatment with cladribine tablets 3.5mg/kg resulted in selective reductions in B and T lymphocytes.
Lymphocyte recovery began soon after treatment in each of years 1 and 2. Median ALC recovered to the normal range
and CD19+ B cells recovered to threshold values by week 84, approximately 30 weeks after the last dose of cladribine
tablets in year 2. Median CD4+ T cell counts recovered to threshold values by week 96 (approximately 43 weeks after
the last dose of cladribine tablets in year 2). Median CD8+ cell counts never dropped below the threshold value.
Conclusion: These results show the dynamics of lymphocyte count changes following treatment with cladribine
tablets 3.5 mg/kg. The immune cell repopulation results provide further evidence that cladribine tablets may
represent a form of IRT.
The CLARITY study: NCT00213135.
The CLARITY Extension study: NCT00641537.
The PREMIERE registry: NCT01013350.
1. Introduction
Immune reconstitution therapies (IRT) for patients with multiple
sclerosis (MS) are used for short, intermittent treatment periods to in-
duce immune resetting and allow treatment-free periods
(Giovannoni, 2017; Wiendl, 2017). Cladribine tablets 10mg (MAVEN-
CLAD®) are thought to be an IRT that causes selective and transient
reductions in CD19+ B cells and T cells, followed by reconstitution of
the adaptive immune system (Giovannoni, 2017; Wiendl, 2017). Cla-
dribine is a prodrug which is phosphorylated intracellularly to its active
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form, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), by deox-
ycytidine kinase, and Cd-ATP is degraded by 5′-nucleotidase
(Beutler, 1992; Comi et al., 2013). Lymphocytes contain a higher
deoxycytidine kinase to 5′-nucleotidase activity ratio than other cells
types, which means Cd-ATP accumulates to high levels in lymphocytes,
and thus causes the selective reduction of these cells (Beutler, 1992;
Comi et al., 2013).
Cladribine tablets have been approved for the treatment of highly
active relapsing MS (RMS) in the European Union (EU) (Merck Serono
Europe Limited, 2017). Cladribine 10mg tablets are given as a cumula-
tive oral dose of 3.5mg/kg over 2 years (henceforth referred to as cla-
dribine tablets 3.5mg/kg), administered as 1 treatment course of
1.75mg/kg per year in each of the 2 years. In the EU Summary of Pro-
duct Characteristics (SmPC), criteria for initiating and continuing treat-
ment with cladribine tablets are based on absolute lymphocyte count
(ALC) being normal (Common Terminology Criteria for Adverse Events;
[CTCAE] Grade 0) before treatment in the first year and ≥0.8×109
cells/L (CTCAE Grade 1 or 0) before treatment in the second year.
In the Phase III CLARITY study, a cumulative dose of cladribine ta-
blets 3.5mg/kg given over 2 years was shown to significantly reduce
relapse rates, risk of disability progression, and magnetic resonance
imaging (MRI) measures of disease activity vs. placebo in patients with
RMS (Giovannoni et al., 2010). In patients who subsequently received
placebo in the CLARITY Extension study, clinical benefits were main-
tained for a further 2 years with no additional active treatment, de-
monstrating the durable efficacy of cladribine tablets 3.5mg/kg
(Giovannoni et al., 2017). The safety profile of cladribine tablets 3.5mg/
kg has been broadly described in a companion safety publicationMultiple
Sclerosis and Related Disorders (Cook et al., 2018). Data presented in the
companion publication are primarily from a pooled analysis of Phase III
clinical trials for patients with early to more advanced RMS receiving the
approved dose of cladribine tablets 3.5mg/kg as monotherapy (the
CLARITY, CLARITY Extension and ORACLE-MS studies, plus follow-up in
the PREMIERE registry; the ‘Monotherapy Oral’ cohort). The companion
manuscript also includes data from an All Exposed cohort of patients who
were exposed to cladribine by any route of administration or at higher
doses during the clinical development program in multiple sclerosis
(MS). This cohort pooled patients from the same trials used for the
Monotherapy Oral cohort, together with patients from the ONWARD
study of cladribine tablets with concomitant interferon (IFN)-β therapy,
plus 5 trials of parenteral cladribine in patients with MS (Scripps-A, -B
and -C, MS-Scripps and MS-001).
Lymphopenia is an anticipated effect of cladribine treatment, due to
its pharmacological properties and selective depletion of lymphocytes;
in clinical trials, lymphopenia was reported more frequently as an ad-
verse event (AE) for cladribine tablets 3.5mg/kg than for placebo
(adjusted AE incidences per 100 patient years 7.94 vs. 1.06 for placebo)
(Cook et al., 2018). Monitoring of lymphopenia during treatment with
disease modifying drugs (DMDs) for MS is relevant because of the po-
tential for an associated increase in risk of infections. A post-hoc analysis
of the Monotherapy Oral cohort reported in the companion publication
examined infectious AEs occurring during periods of severe (Grade 3 or
4) lymphopenia in patients treated with cladribine tablets 3.5mg/kg.
Severe lymphopenia (ALC <0.5× 109 cells/L) resulted in an increased
frequency of infections. However, the infectious AE profile observed
during periods of Grade 3 and 4 lymphopenia did not differ from that
seen outside of these periods.
Interactions between the innate and adaptive immune system are
involved in the prevention of cancer development, and patients with
profound immunosuppression (e.g., patients with HIV-AIDS, idiopathic
CD4+ lymphopenia, or transplant patients who are treated with
strongly immunosuppressive therapy) have an increased cancer risk
(Oliveira Cobucci et al., 2012; Ahmad et al., 2013). Lymphoprolifera-
tive disorders and non-melanoma skin cancer (NMSC) occur frequently
in patients with profound immunosuppression (Didona et al., 2018;
McPherson and Kirk, 2017; Perez et al., 2017). In the integrated safety
analysis of clinical trials with cladribine in patients with MS, no lym-
phoproliferative disorders and no increased risk of NMSC vs. placebo
were observed in either the Monotherapy Oral or All Exposed cohorts
(Cook et al., 2018).
In order to examine the incidence of and recovery from lymphopenia
during treatment with cladribine tablets in detail, here, we report data from
a pooled patient cohort most suitable for analysis of lymphocyte count
dynamics over time. Data from RMS patients in CLARITY (Giovannoni et al.,
2010), CLARITY Extension (Giovannoni et al., 2017) and the PREMIERE
registry (‘Long-term CLARITY’ cohort) allowed long-term follow-up of the
lymphocyte counts. In patients receiving placebo or cladribine tablets
(3.5mg/kg cumulative dose) administered as two short (4 or 5 days) weekly
treatments at the start of months 1 and 2 in each treatment year, followed
by no further active treatment, ALC was analyzed up to 312 weeks, and B
and T cell subsets up to 240 weeks after the first administered dose.
2. Methods
2.1. Long-term CLARITY cohort
Longitudinal lymphocyte data are provided by pooled analyses of
double-blind studies in which patients with RMS were treated with
placebo or cladribine tablets 3.5 mg/kg as monotherapy (the current
approved dose) (Merck Serono Europe Limited, 2017). Data were
pooled from 2 Phase III studies that involved treatment with cladribine
tablets 3.5 mg/kg; CLARITY (Giovannoni et al., 2010) and CLARITY
Extension (Giovannoni et al., 2017), and in patients from these studies
followed up in the Prospective Observational Long-term Safety Registry
of Multiple Sclerosis Patients Who Have Participated in Cladribine
Clinical Trials (PREMIERE registry).
Patients randomized to cladribine tablets 3.5mg/kg in CLARITY were
pooled with those who received cladribine tablets 3.5mg/kg for the first
time in CLARITY Extension (following placebo in CLARITY). Baseline was
defined as the date of treatment initiation with cladribine tablets 3.5mg/
kg in both trials. After 2 years’ treatment with cladribine tablets, no further
active treatment was administered in these patients. Patients randomized
to placebo in CLARITY were assigned to cladribine tablets 3.5mg/kg in
CLARITY Extension for ethical reasons. Therefore, clinical trial data for the
placebo group in this report are limited to 2 years (plus follow-up in the
PREMIERE registry). It is of note that this includes the bridging intervals in
treatment between CLARITY and CLARITY Extension and prior to the
PREMIERE registry, periods during which the lymphocyte counts of pa-
tients were not monitored. The limited number of patients who received
IFN-β as rescue therapy (n=11; <3% of patients treated with cladribine
tablets 3.5mg/kg) were not excluded or censored.
2.2. Analyses
ALC was measured as part of a complete blood count performed by a
central laboratory with CD19+ B cells, CD4+ T cells, and CD8+ T cells
quantified in a subset of patients using flow cytometry as part of a
lymphocyte surface marker analysis. Threshold counts were defined as
0.10×109, 0.35× 109, and 0.20×109 cells/L for CD19+ B cells, and
CD4+ and CD8+ T cells, respectively. Thresholds for CD19+ B cells and
CD8+ T cells were chosen based on values used in previous studies of
disease modifying drugs (DMDs) for multiple sclerosis (Hill-
Cawthorne et al., 2012), and the threshold for CD4+ T cells was chosen
based on the value used for initiating antiretroviral therapy in patients
with human immunodeficiency virus, below which there is an increased
risk of infection (Vitoria et al., 2013). All analyses were performed
using SAS® Software version 9.2 or later.
3. Results
In the Long-term CLARITY cohort, patients exposed to cladribine
tablets 3.5mg/kg (n=685) were more numerous than patients
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receiving only placebo (n=435) and were followed over a longer
period (Table 1). Patient demographics were similar between the cla-
dribine tablets 3.5mg/kg and placebo treatment groups (Table 1).
3.1. Absolute lymphocyte counts
Median ALC over time is shown in Fig. 1. In the cladribine tablets
3.5 mg/kg group, ALC fell initially following treatment and lymphocyte
recovery began soon afterwards in year 1 and year 2. During year 1,
median (interquartile range) ALC reached a nadir of 1.00×109 cells/L
(0.80; 1.30) at 2 months after start of treatment in the group treated
with cladribine tablets 3.5mg/kg. At the end of year 1 (48 weeks),
median ALC had increased to 1.21× 109 cells/L (0.95; 1.50). During
year 2, median ALC in the group treated with cladribine tablets 3.5 mg/
kg reached a nadir of 0.81×109 cells/L (0.60; 1.04) at 55 weeks (i.e.
week 7 in year 2). Median ALC returned to the normal range
(1.00×109 cells/L [0.76; 1.30]) (Territo, 2019) by 84 weeks (week 36
in year 2), increasing to 1.03× 109 cells/L (0.80; 1.30) at the end of
year 2 (96 weeks). Median ALC returned to the normal range in 75% of
patients treated with cladribine tablets 3.5mg/kg by 144 weeks. In
patients randomized to placebo, median ALC was between 1.69×109
and 1.95× 109 cells/L over the 4-year period (low numbers of patients
were available for analysis).
3.2. B lymphocyte counts
Median CD19+ B cell counts were 0.205× 109 cells/L (0.143;
0.265) at baseline in patients treated with cladribine tablets 3.5 mg/kg
(Fig. 2). After treatment in year 1, CD19+ B cells reached a nadir at 2
months (median 0.018×109 cells/L [0.010; 0.035]), and then in-
creased rapidly. After treatment in year 2, a nadir was observed at 52
weeks (median 0.031× 109 cells/L [0.020; 0.058]). CD19+ B cells then
rapidly recovered, reaching the threshold of 0.100×109 cells/L by 84
weeks, and continuing to improve thereafter. Recovery to threshold
values occurred approximately 30 weeks after the last dose of cla-
dribine tablets in each treatment year. In patients randomized to pla-
cebo, median CD19+ B cell counts were between 0.193× 109 and
0.225× 109 cells/L.
3.3. T lymphocyte counts
Median CD4+ T-cell counts in patients treated with cladribine tablets
3.5mg/kg were 0.851×109 cells/L (0.652; 1.051) at baseline (Fig. 3).
After treatment in year 1, median CD4+ T cells reached a nadir at 4 months
(0.385×109 cells/L [0.292; 0.578]) and then gradually increased. Median
CD4+ T cells reached a nadir after treatment in year 2 at 60 weeks
(0.292×109 cells/L [0.212; 0.429]). Values then gradually recovered,
exceeding the threshold of 0.350×109 cells/L by 96 weeks (around 43
weeks after the last dose of cladribine tablets in year 2), and continuing to
improve thereafter. In patients randomized to placebo, median CD4+ T cell
counts were between 0.746×109 and 0.822×109 cells/L.
Median CD8+ T cell counts were 0.378×109 cells/L (0.283; 0.540)
at baseline in patients treated with cladribine tablets 3.5mg/kg (Fig. 4).
CD8+ T cells reached a nadir in year 1 at 4 months (median 0.239×109
cells/L [0.146; 0.384]), and then gradually increased. A nadir in year 2
was reached at 72 weeks (median 0.232×109 cells/L [0.155; 0.335]).
Median CD8+ T cells recovered after treatment and never dropped below
the lower limit of normal of 0.200×109 cells/L at any time in the 240-
week observation period. In patients randomized to placebo, median
CD8+ T cell counts were between 0.373×109 and 0.424×109 cells/L.
The decrease in CD8+ T cells after treatment with cladribine tablets
3.5 mg/kg was less pronounced compared with the decrease in CD4+ T
cells, and the recovery was faster, meaning that the CD4+/CD8+ ratio
was temporarily decreased.
4. Discussion
Due to its established mode of action, treatment with cladribine ta-
blets results in selective reduction of B and T lymphocytes. Lymphocyte
reductions following treatment with cladribine tablets are relatively
gradual, in comparison with the very rapid reductions seen after treat-
ment with monoclonal antibodies with a cytolytic mode of action
(Baker et al., 2017a; Montalban et al., 2017). Consequently, treatment
with cladribine tablets does not require comedication (Merck Serono
Europe Limited, 2017) to alleviate the cell lysis syndrome that occurs
with monoclonal antibodies. Preclinical data shows that cladribine can
also reduce the secretion of inflammatory cytokines and chemokines in
human and murine dendritic cells (Kraus et al., 2014).
Recovery of lymphocyte counts begins soon after treatment with cla-
dribine tablets in year 1 and year 2. Furthermore, median ALC and CD19+
B cell counts recovered to threshold values by approximately 30 weeks after
the last dose of cladribine tablets in year 2. Median B cell counts stabilized
upon returning to baseline and did not exceed baseline levels, potentially
explaining the lack of secondary B cell autoimmunity which has been ob-
served after treatment with other DMDs for MS. (Baker et al., 2017b)
Median CD4+ T cell counts recovered to threshold values by approximately
43 weeks after the last dose of cladribine tablets in year 2, and median
CD8+ cell counts never dropped below the threshold value. Effects of
treatment with cladribine tablets on other lymphocyte subsets is also of
interest – more detailed immunophenotyping, including extensive data from
the ORACLE-MS study, will be the subject of a separate report.
In the CLARITY and CLARITY Extension studies, Grade 3 lympho-
penia (ALC 0.2–<0.5× 109 cells/L) was experienced by 25% of pa-
tients and Grade 4 lymphopenia (<0.2×109 cells/L) was experienced
by <1% of patients treated with cladribine tablets 3.5mg/kg
(Giovannoni et al., 2010; Giovannoni et al., 2017). The EU SmPC for
cladribine tablets states that the treatment course in year 2 can be
delayed for up to 6 months to allow for recovery of lymphocytes, but if
recovery takes more than 6 months, the patient should not receive
further treatment (Merck Serono Europe Limited, 2017). When the
ALC-based treatment scenarios were investigated in a clinical trial si-
mulation based on the CLARITY study in order to assess the impact of
postponing treatment in the second year on the risk of severe lym-
phopenia (Terranova et al., 2018), it was predicted that by allowing a 6
month delay, ∼99% of patients would be eligible for the second year
Table 1
Baseline demographics and clinical characteristics for patients included in the
Long-term CLARITY cohort.
Placebo
(N=435)
Cladribine tablets
3.5mg/kg
(N=685)
Time on study in weeks, mean (SD) 168.67 (116.70) 205.13 (117.48)
Time on study ≥24 weeks (∼6
months), n (%)
418 (96.1) 669 (97.7)
Time on study ≥48 weeks (∼1
year), n (%)
399 (91.7) 656 (95.8)
Time on study ≥96 weeks (∼2
years), n (%)
337 (77.5) 597 (87.2)
Time on study ≥192 weeks (∼4
years), n (%)
91 (20.9) 286 (41.8)
Time on study ≥384 weeks (∼8
years), n (%)
60 (13.8) 93 (13.6)
Age (years),a Mean (SD)
Median
Min; Max
38.7 (9.9)
38.0
18; 64
38.2 (10.1)
38.0
18; 65
Age ≤40 years,a n (%) 247 (56.8) 400 (58.4)
Age >40 years,a n (%) 188 (43.2) 285 (41.6)
Female, n (%) 286 (65.7) 462 (67.4)
Prior treatment with DMD, n (%) 131 (30.1) 184 (26.9)
Disease duration in years, mean
(SD)
8.91 (7.39) 7.90 (6.91)
DMD, disease modifying drug; SD, standard deviation.
*a Baseline was defined as the start of the core studies for these parameters.
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course having recovered to ALC ≥0.8× 109 cells/L. The ALC-based
treatment guidelines were employed throughout the ORACLE-MS
study, and the median duration of Grade ≥3 lymphopenia was reduced
from 5.4 months (as observed in CLARITY) to 3.0 months (as observed
in ORACLE-MS) and the incidence of Grade 4 lymphopenia was 0.4%
(European Medicines Agency, 2017). A post-hoc analysis of patients
Fig. 1. Median absolute lymphocyte counts over time in the cladribine tablets 3.5 mg/kg and placebo groups. Visits with sample size ≥30 are displayed. Reproduced
with permission from Giovannoni (2017).
Fig. 2. Median CD19+ B lymphocyte counts over time in the cladribine tablets 3.5 mg/kg and placebo groups. Visits with sample size ≥30 are displayed.
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randomized to cladribine tablets 3.5mg/kg in CLARITY followed by
cladribine tablets 3.5 mg/kg in CLARITY Extension (n=186), i.e. a
cumulative dose of 7mg/kg over 4 years, is reported in the Supple-
mentary Information. Additional courses of treatment did not
numerically decrease the proportion of patients recovering to Grade
0–1 lymphopenia at the end of each treatment year, in patients that met
ALC-based treatment criteria at the start of each treatment year (Sup-
plementary Fig. 1A).
Fig. 3. Median CD4+ T lymphocyte counts over time in the cladribine tablets 3.5 mg/kg and placebo groups. Visits with sample size ≥30 are displayed.
Fig. 4. Median CD8+ T lymphocyte counts over time in the cladribine tablets 3.5 mg/kg and placebo groups. Visits with sample size ≥30 are displayed.
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The current study focused on lymphocyte counts in peripheral
blood. A key unresolved question with cladribine tablets in the treat-
ment of RMS is the effect on tissue-infiltrating lymphocytes, particu-
larly in the central nervous system (CNS). Unlike monoclonal anti-
bodies, which appear to have limited access to the CNS, cladribine is a
small molecule with detectable distribution into tissues, including the
CNS (Saven et al., 1996; Kearns et al., 1994). While it has been pro-
posed that the concentrations of cladribine achieved in the CNS may be
capable of causing apoptosis in lymphoblasts (Freyer et al., 2015), it is
not yet clear how the concentrations achieved in the CNS with the ta-
blet formulation and in therapeutic doses appropriate for RMS would
directly affect adaptive immune cell function in the brain and spinal
cord. Nevertheless, treatment with cladribine tablets 3.5mg/kg fol-
lowed by placebo demonstrated a durable reduction of clinical and MRI
markers of inflammatory disease activity characteristic of MS. There
was no rebound of clinical or MRI activity even after recovery of ALC
(Giovannoni et al., 2017; Comi et al., 2018). This suggests some form of
qualitative change in the adaptive immune response after treatment
with cladribine tablets.
Recent studies of cladribine tablets treatment effects on innate im-
mune cells (Soelberg Sorensen et al., 2017) showed that up to 4 years
after initiating treatment with cladribine tablets 3.5mg/kg median
neutrophil counts never dropped below the normal range. Median
monocyte counts were 0.40×109 cells/L at baseline and ranged from
0.34–0.36×109 cells/L at the end of years 2–4. Median natural killer
cells were transiently reduced after treatment with cladribine tablets,
with an early decrease followed by rapid recovery with cell count ranges
largely overlapping those of placebo-treated patients (Stuve et al., 2017).
The companion publication describing an integrated safety analysis
(Cook et al., 2018) provides more detailed information on AEs related
to lymphopenia from the Monotherapy Oral cohort. Although severe
lymphopenia in patients treated with cladribine tablets 3.5mg/kg re-
sulted in an increased frequency of infections, the infectious AE profile
observed during periods of Grade 3 and 4 lymphopenia did not differ
from that seen outside of these periods. Opportunistic infections that
could be life-threatening (e.g., progressive multifocal leukoencephalo-
pathy, cryptococcosis, toxoplasmosis, pneumocystis jirovecii pneu-
monia, or cytomegalovirus infection) were not observed in patients
treated with cladribine tablets. Infections commonly observed with
IRTs that impact innate immunity (e.g., listeriosis) (Holmoy et al.,
2017) were not observed with cladribine tablets. The results reported in
this publication, and the apparently minimal or no impact on certain
aspects of innate immune function, including monocyte and neutrophil
counts and infectious AE profile, support the notion that cladribine
tablets selectively and transiently reduce adaptive immune cells while
preserving certain components of the innate immune system.
Conclusion
The current study shows that total lymphocytes, CD19+ B cells and
CD8+ T cells recovered to their respective normal ranges after treat-
ment with cladribine tablets 3.5mg/kg over a time period when effi-
cacy was otherwise shown to be maintained, with no resurgence of
clinical or MRI disease activity (Giovannoni et al., 2016). CD4+ levels
recovered more slowly, but without evidence of the opportunistic in-
fection risk that would be expected from long-term T cell reductions.
The immune cell repopulation results presented here provide further
evidence that cladribine tablets may represent a form of IRT.
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